A simple and general strategy for postsurgical personalized cancer vaccine therapy based on an injectable dynamic covalent hydrogel,Biomaterials Science

当前位置： X-MOL 学术 › Biomater. Sci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A simple and general strategy for postsurgical personalized cancer vaccine therapy based on an injectable dynamic covalent hydrogel
Biomaterials Science ( IF 5.8 ) Pub Date : 2021-08-26 , DOI: 10.1039/d1bm01000j
Zhentao Yu _{1,

2} , Yudi Xu _{2,

3} , Haochen Yao _{2,

4} , Xinghui Si _{2,

5} , Guofeng Ji _{1,

2} , Si Dong _{2,

6} , Jiayu Zhao _{2,

7} , Zhaohui Tang _{2,

5,

7} , Xuedong Fang ₁ , Wantong Song _{2,

5} , Xuesi Chen _{2,

5,

7}

Affiliation

Cancer vaccines artificially stimulate the immune system against cancer and are considered the most promising treatment of cancer. However, the current progress in vaccine research against cancer is still limited and slow, partially due to the difficulties in identifying and obtaining tumor-specific antigens. Considering surgery as the first choice for tumor treatment in most cases, the authors evaluated whether the resected tumor can be directly used as a source of tumor antigens for designing personalized cancer vaccines. Based on this idea, herein, the authors report a dynamic covalent hydrogel-based vaccine (DCHVax) for personalized postsurgical management of tumors. The study uses proteins extracted from the resected tumor as antigens, CpG as the adjuvant, and a multi-armed poly(ethylene glycol) (8-arm PEG)/oxidized dextran (ODEX) dynamically cross-linked hydrogel as the matrix. Subcutaneous injection of DCHVax recruits dendritic cells to the matrix in situ and elicits robust tumor-specific immune responses. Thus, it effectively inhibits the postoperative growth of the residual tumor in several murine tumor models. This simple and personalized method to develop cancer vaccines may be promising in developing clinically relevant strategies for postoperative cancer treatment.

中文翻译：

基于可注射动态共价水凝胶的手术后个性化癌症疫苗治疗的简单通用策略

癌症疫苗人为地刺激免疫系统对抗癌症，被认为是最有希望的癌症治疗方法。然而，目前针对癌症的疫苗研究进展仍然有限且缓慢，部分原因是难以识别和获得肿瘤特异性抗原。考虑到手术是大多数情况下肿瘤治疗的首选，作者评估了切除的肿瘤是否可以直接作为肿瘤抗原的来源，用于设计个性化的癌症疫苗。基于这一想法，作者在此报告了一种基于动态共价水凝胶的疫苗 (DCHVax)，用于肿瘤的个性化术后管理。该研究使用从切除肿瘤中提取的蛋白质作为抗原，CpG作为佐剂，和多臂聚（乙二醇）（8臂PEG）/氧化葡聚糖（ODEX）动态交联的水凝胶作为基质。皮下注射 DCHVax 将树突细胞募集到基质中原位并引发强大的肿瘤特异性免疫反应。因此，它有效地抑制了几种鼠肿瘤模型中残留肿瘤的术后生长。这种开发癌症疫苗的简单且个性化的方法可能有希望开发用于术后癌症治疗的临床相关策略。

更新日期：2021-09-10

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11